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Abstract
Over the past decade, the gut microbiome has emerged as a novel and largely untapped source of 
variability for metabolic and cardiovascular disease risk, including diabetes. Animal and human 
studies support several possible pathways through which the gut microbiome may impact health, 
including the production of health-related metabolites from dietary sources. Diet is considered 
important to shaping the gut microbiota; in addition, gut microbiota influence the metabolism of 
many dietary components. In the present paper, we address the distinction between compositional 
and functional analysis of the gut microbiota. We focus on literature that highlights the value of 
moving beyond surveys of microbial composition to measuring gut microbial functioning to 
delineate mechanisms related to the interplay between diet and gut microbiota in cardiometabolic 
health.
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Introduction
There is an intimate relation between diet and the gut flora. Gut microbial communities have 
co-evolved with host species to provide unique metabolic functions, as reflected in broad 
patterns of food consumption, with distinct microbiota among carnivores, omnivores, and 
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herbivores[1, 2]. Geographic surveys in humans reveal differences in microbiota 
corresponding to the extent of plant and animal consumption or Westernization of diet[3–5]. 
On an individual level, dietary composition contributes, at least in part, to shaping the gut 
microbiota through the delivery of energy for microbial growth[6–8]. In turn, gut microbiota 
influence the production of health-related metabolites from dietary components[9, 10], with 
the potential for personal variability in metabolite production based on differences in gut 
microbiota[11, 12]. A growing literature supports a role for gut microbiota in the 
development and progression of metabolic and cardiovascular disease risk[13–16], including 
type 2 diabetes[17–19], obesity[20–22], insulin resistance[23], inflammation[24], 
atherosclerosis[12, 25], hypertension[26, 27], dyslipidemia[28], and cardiovascular disease 
events[29, 30]. The purpose of the current review is to frame a discussion around the 
complex interplay between diet and and available assessments of the gut microbiota in 
pathways to metabolic disease. Additionally, we will review evidence supporting the 
growing emphasis in the field to move from surveys of taxonomic composition of the 
microbial community to measuring microbiota functional potential and activity for improved 
understanding of health-related pathways through microbiota.
Studying the gut microbiota, diet, and cardiometabolic health: From 
microbiota composition to function
Measuring the gut microbiota: a brief introduction
Historically, study of the gut microbiota focused on distinct organisms or a set of specific 
organisms using culture-dependent approaches[31–33]. However, time- and labor-intensive 
culture-based methods require the development of appropriate media for the laboratory 
cultivation of specific microorganisms, limiting the scope of the gut community that can be 
studied. The introduction of culture-independent methods allowed the direct isolation of 
microbial DNA from collected samples, such as fecal samples for study of the gut 
microbiota, and enabled researchers to begin to characterize the larger gut microbial 
community[34]. This work provided key insights into taxonomic composition and 
functionality of the gut microbiota as a whole. Past-decade advances in high-throughput 
(next-generation) sequencing technology have dramatically improved the ease and cost of 
sequencing, contributing to a rapid acceleration of research in the area[35, 36]. Culture-
independent DNA-based approaches have revealed a vast and more diverse community than 
previously appreciated based on culture-dependent approaches, since many gut microbiota 
identified through culture-independent methods had not previously been cultivated.
Gut microbiota composition: Challenges for studies of diet and health
To date, microbiome research has largely focused on measures of microbial composition 
based on sequencing one or more regions of the 16S rRNA marker gene[37–40]. 16S rRNA 
is an evolutionarily well-conserved prokaryotic gene found in all bacteria and archaea, with 
sufficient variability in gene regions to allow taxonomic assignment of microbiota to the 
genus level[41]. Characterization of the gut microbiota based on 16S rRNA include the 
relative abundance of specific taxonomic groups, as well as ecologic measures of the 
microbiome as a whole, such as diversity and richness[38].
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16S rRNA remains easiest, fastest, and most affordable approach for characterizing the 
microbial community with respect to taxonomic composition, but it is limited in its ability to 
provide detailed understanding of gut microbiota functioning. High-throughput sequencing 
technology has made it economically feasible for researchers to further examine the role of 
the gut microbiota in health by obtaining a comprehensive survey of genes in the microbiota, 
using whole genome sequencing (WGS), termed metagenomics[40]. WGS data allows 
taxonomic assignment at a finer level than 16S rRNA and profiles the genes present in the 
microbiota, which can be mapped to metabolic pathways, providing a measure of functional 
potential[42].
The NIH-funded Human Microbiome Project (HMP) generated 16S rRNA and WGS data 
for microbial communities from multiple body locations, including gut, in roughly 300 U.S. 
adults[43]. A primary goal of the HMP was to establish the taxonomic entities and 
composition that constitute a healthy gut microbiota in humans[44]. However, a clearly-
defined core microbiota has defied easy identification; rather, the HMP and other studies 
have found large variation in the taxonomic composition of the gut microbiota among 
healthy individuals[43]. For example, initial animal and human studies supported 
associations between obesity and the ratio of Firmicutes to Bacteroidetes, the two most 
abundant phyla in the human gut microbiota. In one study, ob/ob mice had a greater 
abundance of Firmicutes relative to Bacteroidetes (F/B ratio) than lean mice[45]. A study of 
12 human subjects also found that obese individuals had a higher F/B ratio[20]. In an 
intervention of calorie-restricted diets, weight loss was associated with decreases in F/B, 
irrespective of macronutrient composition (low-fat or low-carbohydrate)[20]. Although 
several subsequent studies reported similar findings, however, other studies showed no F/B 
difference between obese and lean individuals, the reverse association (lower F/B in obese 
vs. lean), or no change in F/B with weight loss[46].
Other research has revealed large within-phyla variability that may help explain inconsistent 
findings. In a study of obese mice fed a Western-style diet, weight gain was accompanied by 
increases in specific members of Firmicutes from the Mollicutes class[47]. In another animal 
study, a high-fat diet was associated with increases in Mollicutes, as well as Firmicutes 
classes Clostridiales and Delta-Proteobacteria[48]. In a dietary intervention among 14 
overweight men, carbohydrate subtype did not reveal a change in F/B, but did show changes 
at lower taxonomic levels[49]. Additional evidence of the importance of more refined 
taxonomic analysis can be illustrated by findings related to Prevotella, one of the two 
primary genera in the phylum Bacteroidetes. Prevotella has been associated with plant-based 
diets[50, 51] and improved glucose metabolism[52], but also with chronic inflammation[53]. 
Such apparent discordance in health associations may reflect within-genus variability. 
Indeed, gene-level diversity has been observed among genomes of strains within a single 
Prevotella species[52]. These data support the need for finer compositional analysis than has 
been standard, as well as motivate increased focus on measures of microbial function.
In contrast to the large compositional variability, functional potential measured through 
WGS is relatively stable among healthy individuals[21, 43]. These findings support a model 
of redundancy in the presence of genes for core metabolic functions across a diverse gut 
microbial composition. Additional work is needed to improve our understanding of how 
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gene sets align with specific microorganisms, particularly to inform our assessment of the 
functional impact of microorganism-based targeted interventions. Redundancy in gene 
presence across microbiota may underlie the finding that greater microbial diversity is 
generally positively associated with health status[21], with some exceptions, as a diverse 
microbiota may be more likely to capture the core set of necessary genes.
Metagenomics studies have revealed significant differences in bacterial genes and metabolic 
pathways in obese and lean twins[21] and among individuals with and without T2D[17, 18]. 
In a study of 345 Chinese adults with and without T2D, WGS was used to derive species-
level compositional information as well as to functionally annotate the gut community[17]. 
Although specific microbiota were differentially enriched in the T2D and control samples, 
there were even greater differences in functional potential, most notably with respect to 
decreased butyrate-producing bacteria among individuals with T2D[17]. Other 
metagenomics studies of T2D also support a role for butyrate production in distinguishing 
T2D from controls[18, 54].
There is growing consensus that to truly delineate the role of the gut microbiota in human 
physiology, we must pursue measures of microbial functional activity. This shift is reflected 
in Phase 2 of the HMP, the integrated Human Microbiome Project (iHMP), which includes a 
collection of multiple functional measures, including transcriptomics (RNA-seq), 
metabolomics, and proteomics[55] The trend towards functional measures in studies of the 
gut microbiota mirrors the current emphasis on integrating host-level functional measures 
into animal models and human studies[56, 57]. Functional measures reflect the biologic 
activity of ultimate physiologic interest; with respect to the gut community, functional 
redundancy across taxonomic groups limit the ability to infer functional activity from 
community composition. Thus, functional analysis will be increasingly important for 
defining microbial pathways to metabolic disease, and for determining targets for 
intervention.
Production of dietary metabolites as a functional measure of gut microbiota
The gut microbiota has evolved complementary metabolic capacity to its human host, and a 
substantial proportion of circulating metabolites have microbial origin[9, 10]. A subset of 
microbiota-related metabolites derive from dietary components[58], several of which have 
been studied with respect to cardiometabolic outcomes. For example, short-chain fatty acids 
generated from microbial metabolism of non-digestible polysaccharides, and in particular 
butyrate, have been shown to have positive effects on glucose and lipid metabolism[59]. 
Phenolic compounds undergo extensive gut microbiota metabolism, and these metabolites 
may help explain the health benefits associated with a plant-based diet[60]. Microbiota-
dependent metabolites may also have adverse effects on cardiometabolic health, such as 
trimethylamine N-oxide (discussed below)[12, 29, 30].
The extent to which metabolites from dietary components are dependent on the gut 
microbiota for production can be estimated in germ-free (gnotobiotic) animal models, which 
lack gut microbiota. Comparing germ-free and conventional mice, Wikoff and colleagues 
reported variable production of metabolites[10]. For example, hippuric acid, produced from 
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gut microbial metabolism of phenolic compounds such as in tea, wine, and fruit juices, was 
17.4 times higher in conventional as compared to germ-free mice. Equol sulfate and p-cresol 
sulfate, produced from isoflavones and amino acids, respectively, were only observed in 
conventional mice.
Based on this and related work, circulating concentrations of microbiota-dependent 
metabolites in host urine or blood have been proposed as relatively efficient measures of 
microbial function, particularly at this stage of the science where metabolic pathways 
through the gut microbiota remain to be defined. Personalized metabolite profiles have been 
identified under controlled dietary delivery of precursors, and this measure of microbial 
function is maintained upon transfer of host microbiota into germ-free mice (termed, 
humanized germ-free model)[61]. That is, the production of metabolites varied among 
humanized mice in a way that reflected the human host, even when mice were maintained on 
the same diet[61]. Humanized germ-free animals provide an experimental model for 
illustrating the role of human gut microbiota in metabolic of dietary components, and have 
been used to demonstrate rapid shifts in the expression of microbial genes in response to a 
dietary change[62].
Integrated approaches to functional understanding of the interplay of diet 
and gut microbiota in cardiometabolic health
We present two examples that we consider illustrative of integrative approaches to the study 
of diet, gut microbiota function, and cardiometabolic health. These examples highlight what 
will likely be the translational and transdisciplinary nature of future work to define targeted 
interventions related to the gut microbiota.
Example 1: Trimethylamine N-oxide (TMAO)
The potential for nutrient metabolite trimethylamine N-oxide (TMAO) to increase CVD risk 
was identified in a metabolomics screen and confirmed in an independent sample[30]. 
Subsequent work has supported associations between TMAO and cardiovascular 
disease[29], chronic kidney disease[63, 64], and type 2 diabetes[65–67], though significant 
findings have not been consistently observed[68, 69]. Proposed mechanisms for TMAO in 
cardiometabolic risk include platelet activation[70], cholesterol efflux[12], uremic 
toxicity[63], and glucose metabolism[67].
The production of TMA from nutrient precursors, choline[29] and L-carnitine[12], is 
dependent on gut microbiota, with conversion of TMA to TMAO in the liver through flavin 
monooxygenase 3 (FMO3)[71]. Variability in circulating TMAO will thus reflect: 1) 
consumption of dietary precursors, 2) gut microbiota metabolic capability for production of 
TMA, and 3) FMO3 genotype for conversion of TMA to TMAO. A GWAS of mouse and 
human studies revealed that variability in TMAO production is likely more reflective of 
differences in diet and gut microbiota, rather than genetic variation in FMO3[72]. Several 
distinct gut microbial pathways for TMAO production have been identified[73–75] or 
proposed[76].
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The production of TMAO varies among individuals exposed to a dietary challenge of TMAO 
precursors[12, 29, 74, 77]. In a well-controlled egg challenge study, individual-level 
dynamics of plasma TMAO was highly variable over a 24-hour period across 6 study 
participants[77]. Larger choline doses yielded a greater spike in TMAO production over the 
24-hour observation period, but considerable variation in TMAO production was observed 
even at high doses (4–6 eggs, or 476–714 mg choline). Participants were provided 
standardized meals throughout the testing periods to maintain equal precursor contribution 
through diet.
Many sources of choline and L-carnitine are animal products, including fish, eggs, and red 
meat, and it is not surprising that TMAO measured in fasting samples is significantly lower 
among vegans and vegetarians as compared to omnivores[12] and among individuals with 
high, as compared to low, adherence to the Mediterranean diet[51]. Interestingly, long-term 
diet may influence the capacity for TMAO to be produced, perhaps through selection of gut 
microbiota based on nutrient availability. In an L-carnitine challenge in 10 individuals, 
TMAO was produced among omnivores, but not among vegans and vegetarians[12]. In 
addition to microbiota pathways related specifically to TMAO precursors, it is intriguing to 
consider the possibility that consumption of dietary components that are not direct 
precursors of TMAO may impact metabolite production through effects on the gut 
microbiota. For example, recent data indicate that TMAO production may be decreased with 
increased resveratrol[78], a phenol found in red wine, or allicin[79], an organosulfur 
compound found in garlic. These data may be consistent with findings from another dietary 
challenge showing that TMAO production was lower in individuals with less gut microbiota 
richness[80]. Another possibility is that other nutritional components may serve to offset an 
adverse impact of TMAO. For example, fish oil appeared to lessen the adverse effect of 
TMAO on glucose tolerance in mice on a high-fat diet[67], providing a possible explanation 
for fish being both cardioprotective as well as a major contributor of TMA directly and of 
TMA precursors.
This example illustrates the combination of discovery and targeted metabolite analysis in 
observational cohorts, controlled mechanistic work in animal models, and nutrient challenge 
studies in small human samples to elucidate health effects of the gut microbiota-dependent 
metabolite TMAO and pathways to TMAO production from dietary precursors through the 
gut microbiota.
Example 2: Polyphenols: Isoflavones and lignans
Isoflavones and lignans are polyphenols, which are a large class of compounds from plant 
sources[60]. It has been estimated that 90% of polyphenols have incomplete absorption in 
the small intestine and undergo metabolism by microbiota in the lower intestine[81, 82]. 
There is large individual variability in the production of metabolites following consumption 
of dietary polyphenolic precursors, which may reflect differences in gut microbiota. Plant 
consumption and many polyphenols, including isoflavones and lignans, have been proposed 
to be related to a range of health outcomes, including cardiovascular disease and 
diabetes[83, 84]. It is hypothesized that polyphenol metabolites may explain, at least in part, 
the health benefits of plant-based diets. Soy is a rich source of the isoflavone daidzein, from 
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which metabolites equol and O-desmethylangolensin are generated; lignans are found in a 
variety of foods, including rye, berries, and flaxseed, and yield metabolites enterodiol and 
enterolactone. In two cohorts of U.S. women, higher urinary levels of isoflavones and 
lignans metabolites have been inversely associated with T2D[85, 86].
The gut microbiota-dependence of isoflavone and lignan metabolite production was 
demonstrated in a humanized germ-free rat model. Human subjects were classified as high 
or low producers of equol based on their response following consumption of a soy meal[87]. 
Equol, O-desmethylangolensin, and enterolactone were not produced in germ-free rats, but 
were detectable upon introduction of human fecal microbiota. The equol production 
phenotype was transferrable to germ-free rats: rats produced equol when they received a 
fecal microbiota transplant from individuals with high equol production, but not when they 
received a transplant from individuals with low equol production. There is a lack of data on 
microbial pathways for isoflavone and lignan metabolite production, but one recent study 
reported a positive association between gut microbiota diversity, based on 16S rRNA 
analysis, and enterolignan production in 115 premenopausal U.S. women[11].
Equol production is higher in Asian populations and in vegetarians, potentially supporting a 
role for long-term diet in gut microbiota-dependent metabolite production. In one study, 
equol production was 51% in Korean-American women as compared to 36% in non-Korean-
American women[88]. In a U.S. sample of 41 healthy individuals, equol production varied 
from 25% among non-vegetarians (n=12) to 59% among vegetarians (n=29)[89]. However, 
studies of long-term dietary intake and equol production have yielded inconsistent 
results[90, 91]. In addition, research is needed into the extent to which these phenotypes are 
inducible with dietary change. A 1-month soy intervention did not alter ability to produce 
isoflavone metabolites[92]. It is possible that diet is important, but that effects of diet on 
microbiota are not restricted to the direct metabolite precursor.
Metabolite production studies have generally been small-scale highly controlled challenge 
studies. Designs that would allow the measurement of metabolite-producer phenotypes in 
large-scale population-based studies would provide data on the distribution of metabolite 
production in the population, and allow improved study of covariates that influence 
metabolite production, including diet and other lifestyle factors. In addition, larger samples 
are needed to power discovery analysis of microbial components related to metabolite 
production. In a recent study, Melby and Watanabe addressed some of the necessary 
pharmacokinetic considerations for integrating a challenge component into an epidemiologic 
study[93], including the optimal time window for post-challenge sample collection and the 
dose required to distinguish producers from non-producers.
Challenges for delineating the interplay among diet, gut microbiota, and 
cardiometabolic health
The rapid growth of microbiome research has significantly advanced our appreciation of the 
potential for the gut microbiota to impact metabolic and cardiovascular disease risk, but 
there remain several key challenges for future work.
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First, despite the enormous progress in microbiome research, there is a paucity of data that 
establish causality. Alongside broad enthusiasm for the untapped potential of gut microbiota 
for understanding human physiology, there are calls for cautious interpretation of findings 
until data are available that delineate mechanistic pathways through the gut microbiota to 
health[94]. Findings that microbiota functional measures change upon changes in diet are 
compelling, but we do not know whether gut microbiota function is altered through targeted 
dietary interventions or whether changes in metabolite production and gene expression 
reflect existing functional potential that is activated through the delivery of dietary 
precursors. TMAO and isoflavones/lignans case studies are useful illustrations of an 
integrated approach to understanding pathways through diet, but there are few such 
examples in the literature. With respect to health outcomes, data indicate the potential for 
complex inter-connections; for example, obesity may be both influenced by the gut 
microbiota[22] as well as influence the gut microbiota[45]. Most observational studies of the 
microbiome have included a limited set of covariates to control for potential confounders. A 
recent analysis of T2D demonstrates the value of adjustment for medication use to clarifying 
discordant findings in observational studies[54].
Second, there is need for richer microbiota data from well-designed human studies. Model 
systems are exceptional experimental resources, but they may not reflect human biology. 
Germ-free animal models have illustrated the relevance of gut microbiota for health, 
including through the production of certain dietary metabolites[10]. Humanized microbiota-
associated mice have been proposed as an efficient method to determine causality by 
incorporating human-derived gut microbiota in a controlled model organism, but there are 
many questions about the extent to which these models will reflect the active microbiota of 
the source human hosts[95]. Human studies are needed to address the potential lack of 
representation in animal models, as well as to capture the breadth of microbiota existing in 
human populations. For example, the HMP covered a relatively small sample (n~300) with 
little racial/ethnic diversity. To date, most observational studies have been cross-sectional 
comparisons of individuals with and without a health condition, and there is need to 
incorporate microbiota sample collection in ongoing cohort studies. Human experiments 
have been informative, but may not always reflect typical behavior, such as a study 
comparing plant- and animal-based diets[96], which are rare extremes in most societies.
Third, there is increasing recognition of the need for standards in the collection and 
processing of samples, and the analysis of microbiome data. Using a set of generated 
communities with known composition, the extent of possible bias was demonstrated in a 
recent study of vaginal microbiome. This work revealed the potential for large and 
differential-by-organism errors, largely attributable to DNA extraction and PCR 
amplification steps of sample processing[97]. The newly-established Microbiome Quality 
Control project will contribute to elucidating differences stemming from variability in 
methods in the field, the laboratory, and bioinformatics; and providing guidance in the future 
for microbiome researchers[98]. In the interim, protocols from the HMP have been 
published and their use allows comparison with HMP data and other data from researchers 
using the HMP protocols[39].
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Summary and Conclusions
A growing body of literature supports a role of gut microbiota in the development and 
progression of metabolic and cardiovascular disease risk, but precise causal mechanisms 
remain to be elucidated. The microbiota-dependent production of health-related nutrient 
metabolites may be an important pathway through which the microbiota mediates the impact 
of diet on disease risk; however, the complex interplay between diet and the gut microbiota 
is only beginning to be understood. Diet appears to be important to shaping the gut 
microbiota, though the extent to which gut microbiota can be changed for improved health 
through targeted dietary interventions is not known. Multiple dietary components rely on gut 
microbiota for metabolism, and there is large individual variability in the gut microbiota-
dependent production of health-related metabolites. A direction for future research is 
integrating gut microbiota measures into approaches for personalized nutrition[99]. Future 
advances in the field will be aided by shifting to a focus on microbiota functional activity, as 
well as deeper compositional measures to capture important within-species variability, along 
with increased attention to study designs for causal inference, a greater number of well-
designed human studies, and standards for the conduct of microbiome studies.
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